Expert Consensus on the Use of Human Serum Albumin in Critically Ill Patients

0
0
0

Expert Consensus on the Use of Human Serum Albumin in Critically Ill Patients

Introduction
Human serum albumin (HSA), a key plasma protein synthesized by the liver, plays a pivotal role in maintaining colloid osmotic pressure, transporting endogenous and exogenous substances, and exerting anti-inflammatory and antioxidant effects. Hypoalbuminemia (serum albumin <35 g/L) is prevalent in critically ill patients and is independently associated with increased mortality, prolonged hospital stays, and complications such as acute kidney injury (AKI). Despite its widespread use in fluid resuscitation and hypoproteinemia management, the clinical application of HSA remains controversial. This consensus, developed by the Chinese Society of Critical Care Medicine, addresses 11 clinical scenarios in critical care to standardize HSA use and optimize outcomes.

Methodology
The consensus utilized the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Eighteen critical care experts and two evidence-based medicine specialists reviewed literature from PubMed and Cochrane Library, focusing on meta-analyses and randomized controlled trials (RCTs). Clinical questions were structured using the Population, Intervention, Comparison, and Outcome (PICO) format. Recommendations were graded based on evidence strength, ranging from strong (Grade 1+) to weak (Grade 2+/-) or expert opinion.

Key Recommendations

1. Sepsis and Septic Shock

  • Recommendation 1: HSA is safe for sepsis resuscitation and may reduce mortality in septic shock (Grade 2+). The SAFE trial (2004) found comparable safety between 4% HSA and saline, with subgroup analyses suggesting mortality benefits in severe sepsis (RR: 0.87) and septic shock (RR: 0.87). Subsequent ALBIOS and EARSS trials reinforced these findings.
  • Recommendation 2: HSA should be considered if hemodynamic instability persists after 30 mL/kg crystalloid infusion (Expert Opinion). This aligns with SSC guidelines advocating albumin supplementation after initial crystalloid resuscitation.
  • Recommendation 3: Both low- (4–5%) and high-concentration (20–25%) HSA are viable options (Expert Opinion). Meta-analyses found no mortality difference between concentrations.
  • Recommendation 4: Discontinue HSA when serum albumin ≥30 g/L and hemodynamic stability is achieved (Grade 2+). Hypoalbuminemia correlates with complications; maintaining albumin ≥30 g/L reduces morbidity.
  • Recommendation 5: HSA supplementation improves pharmacokinetics of highly protein-bound antibiotics (e.g., ceftriaxone, daptomycin) (Grade 2+). Hypoalbuminemia alters drug distribution, increasing toxicity risks.

2. Hemorrhagic Shock

  • Recommendation 6: Avoid routine HSA use in uncontrolled bleeding (Grade 2–). Crystalloids remain first-line; colloids (including HSA) offer no proven survival benefit.
  • Recommendation 7: Use HSA post-bleeding control to correct hypovolemia and hypoalbuminemia (Grade 2+). Albumin restores vascular integrity and reduces edema, as shown in capillary permeability models.

3. Cardiac Surgery

  • Recommendation 8: Perioperative HSA resuscitation reduces fluid requirements and AKI risk (Grade 2+). A study of 240 cardiac surgery patients demonstrated lower fluid volumes with HSA versus hydroxyethyl starch (HES) or Ringer’s lactate. Albumin also reduced blood loss and transfusion needs by 28–30%.

4. Abdominal Surgery

  • Recommendation 9: Monitor albumin to prevent complications (Grade 2+). Preoperative albumin <40 g/L increases pancreatic fistula and infection risks.
  • Recommendation 10: Use HSA for hypoalbuminemia (Grade 2+). Trials show organ function improvement with albumin infusions in cirrhotic patients undergoing liver transplantation.
  • Recommendation 11: Maintain perioperative albumin ≥30 g/L (Grade 2+). Postoperative levels <30 g/L correlate with prolonged ICU stays.

5. Acute Brain Injury

  • Recommendation 12: Avoid HSA as first-line resuscitation (Grade 2–). SAFE-TBI trial linked 4% HSA to higher mortality (RR: 1.63) in traumatic brain injury.
  • Recommendation 13: HSA may improve outcomes in cerebral hemorrhage (Expert Opinion). Studies suggest reduced midline shift and EEG normalization with 25% albumin.
  • Recommendation 14: Do not use HSA solely for intracranial pressure (ICP) reduction (Expert Opinion). Hypertonic saline/mannitol remain preferred.

6. Trauma

  • Recommendation 15: Avoid HSA in initial trauma resuscitation (Grade 2–). Crystalloids are preferred; SAFE trial subgroup analysis showed no survival benefit.
  • Recommendation 16: Use HSA for hemodynamically unstable trauma patients with severe hypoalbuminemia (Grade 2+). Meta-analyses suggest albumin stabilizes circulation and reduces edema.

7. Burns

  • Recommendation 17: Combine crystalloids and colloids (plasma preferred; 5% HSA as alternative) (Grade 2+). Albumin reduces fluid requirements and edema in shock phases.
  • Recommendation 18: Use HSA during burn shock (Grade 2+). Studies report lower mortality and ventilator dependence with albumin.
  • Recommendation 19: Use hypertonic HSA (≥10%) if albumin <30 g/L (Expert Opinion). High-concentration albumin resolves interstitial edema in later phases.

8. Acute Respiratory Distress Syndrome (ARDS)

  • Recommendation 20: HSA improves oxygenation in hypoalbuminemic ARDS (Grade 2+). Trials show oxygenation index increases of 56–62 mmHg post-infusion.

9. Liver Disease

  • Recommendation 21: Administer HSA post-large-volume paracentesis (LVP) (Grade 2+). ANSWER trial demonstrated reduced refractory ascites (HR: 0.43) and mortality (HR: 0.62).
  • Recommendation 22: Combine HSA with terlipressin for hepatorenal syndrome (HRS) (Grade 2+). This regimen improves HRS reversal (OR: 4.72) and reduces renal replacement needs.

10. Extracorporeal Membrane Oxygenation (ECMO)

  • Recommendation 23: Avoid HSA in ECMO circuit priming (Expert Opinion). Fibrinogen displacement negates theoretical benefits.
  • Recommendation 24: Combine HSA with crystalloids for ECMO resuscitation (Expert Opinion). A study of 283 patients showed higher survival (43.9% vs. 27.6%) with HSA-crystalloid mixes.

11. Adverse Effects

  • Recommendation 25: Monitor for allergic reactions and fluid overload (Expert Opinion). Rare anaphylaxis and AKI risks necessitate careful infusion management. High-concentration HSA (25%) correlates with AKI (OR: 5.99) in shock patients.

Conclusion
This consensus provides evidence-based guidelines for HSA use across critical care scenarios, emphasizing individualized fluid management and albumin supplementation strategies. While HSA offers benefits in specific contexts, such as septic shock, post-LVP ascites, and HRS, its routine use in trauma or uncontrolled hemorrhage is discouraged. Ongoing research is needed to clarify optimal dosing, timing, and patient selection.

DOI: 10.1097/CM9.0000000000001661

Was this helpful?

0 / 0